Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy
Our study suggests that the CDC42 gene set mutations could potentially serve as a novel biomarker for the clinical response to ICI treatment. This finding also provides insights into the potential of combining ICI and CDC42 inhibitor use for more efficient patient treatment.
Authors
- Xiaochu Tong
- Mingyue Zheng (ORCID: https://orcid.org/0000-0002-3323-3092)
- Zhaoming Su (ORCID: https://orcid.org/0000-0002-9279-1721)
- Bei Wang (ORCID: https://orcid.org/0000-0001-5407-7810)
- Yingying Zhang (ORCID: https://orcid.org/0000-0002-3951-0345)
- Kun Wang (ORCID: https://orcid.org/0000-0001-9851-7080)
- Chengying Xie (ORCID: https://orcid.org/0000-0002-3572-5269)
- Yuanyang Zhou
- Sulin Zhang (ORCID: https://orcid.org/0000-0002-9167-4689)
- Xiaomin Luo (ORCID: https://orcid.org/0000-0003-0426-3417)
Institutions
- University of Science and Technology of China (CN)
- Nanjing University of Chinese Medicine (CN)
- ShanghaiTech University (CN)
- Shanghai Institute of Materia Medica (CN)
- Anhui Provincial Hospital (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1002/cam4.70556
- Primary Topic
- Cancer Mechanisms and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
- Youth Innovation Promotion Association of the Chinese Academy of Sciences
- Shanghai University of Traditional Chinese Medicine
- National Key Research and Development Program of China
- Youth Innovation Promotion Association